BioNexus Gene Lab shares surge 13.18% after-hours after securing 15% stake in Fidelion and $500M financing for VitaGuard expansion.

BioNexus Gene Lab (NASDAQ:BGLC) surged 13.18% in after-hours trading following the completion of a strategic transaction with Fidelion Diagnostics and Tongshu Biotechnology, securing a 15% equity stake in Fidelion and exclusive commercial rights to the VitaGuard Tumor-Naïve Minimal Residual Disease liquid biopsy platform across Southeast Asia. The deal, structured as a share swap and installment-based license fee, preserved BGLC’s liquidity while aligning with Fidelion’s future capital-raising potential, including possible Nasdaq or NYSE listings. Additionally, BGLC announced a $500 million Equity Purchase Agreement with ARC Group International Ltd., providing discretionary access to capital over 36 months to advance commercialization and expansion efforts. These developments positioned BGLC as a key player in Southeast Asia’s precision oncology market and enhanced investor confidence in its growth trajectory.